Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE R BLUMENSCHEIN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1346334125
CMS profile
288092
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$8,235.00

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,235.00 3

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $3,610.00 1
NOVARTIS PHARMACEUTICALS CORPORATION $3,125.00 1
Merck Sharp & Dohme Corporation $1,500.00 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE R BLUMENSCHEIN

NPI 1346334125 · CMS profile ID 288092

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346334125?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE R BLUMENSCHEIN, NPI 1346334125, CMS profile ID 288092. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346334125?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). GEORGE R BLUMENSCHEIN, NPI 1346334125, CMS profile ID 288092. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346334125?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
GEORGE R BLUMENSCHEIN, NPI 1346334125, CMS profile ID 288092, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1346334125?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $8,235.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $3,610.0011/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743815439 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $3,125.0011/19/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753369149 CMS
Merck Sharp & Dohme Corporation $1,500.0008/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747626797 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,426.11 7
PY2020 $8,235.00 3
PY2021 $10,571.25 4
PY2022 $9,985.02 9
PY2023 $2,491.76 2
PY2024 $2,739.74 5
PY2025 $5,674.98 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $730.63 2
PY2025 Principal investigator $826,291.13 39
PY2024 Recipient $1,170.09 3
PY2024 Principal investigator $765,367.11 23
PY2023 Principal investigator $220,292.88 22
PY2022 Principal investigator $222,960.12 18
PY2021 Principal investigator $1,840,171.85 42
PY2020 Principal investigator $805,658.52 8
PY2019 Recipient $886.00 1
PY2019 Principal investigator $1,441,336.92 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,539.00 12/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184142959
Principal investigator 1 Daiichi Sankyo Inc. $14,300.00 12/18/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
DS1062-A-U202 No dispute reported 06/30/2026 1223360545
Principal investigator 1 BeOne Medicines Ltd. $2,885.00 12/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190329793
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,657.60 12/05/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223273047
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,120.00 12/05/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223273049
Principal investigator 1 Daiichi Sankyo Inc. $91,710.11 10/14/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
DS1062-A-U202 No dispute reported 06/30/2026 1223360543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,597.92 10/09/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184142703
Principal investigator 1 BeOne Medicines Ltd. $2,553.00 09/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190329203
Recipient Regeneron Pharmaceuticals, Inc. $464.97 09/08/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184115743
Principal investigator 1 BeOne Medicines Ltd. $5,106.00 09/02/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190329205
Principal investigator 1 Genentech, Inc. $35,776.65 08/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Inflamed Solid Tumors PD1 TIM3 Ph1 study in Solid Tumors No dispute reported 06/30/2026 1211564102
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,500.00 08/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
TAK-280-1501 No dispute reported 06/30/2026 1223273023
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 08/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
TAK-280-1501 No dispute reported 06/30/2026 1223273025
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,120.00 08/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
TAK-280-1501 No dispute reported 06/30/2026 1223273027
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $29,151.00 08/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
TAK-280-1501 No dispute reported 06/30/2026 1223273029
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,390.90 07/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SoC Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and IIIA Non-small Cell Lung Cancer (NeoADAURA) No dispute reported 06/30/2026 1185542150
Principal investigator 1 BeOne Medicines Ltd. $2,553.00 07/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190329207
Principal investigator 1 PFIZER INC. $40,382.50 07/14/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228722748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,250.00 06/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184142225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,313.70 06/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184142227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 06/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184142229
Principal investigator 1 BeOne Medicines Ltd. $3,095.00 06/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190331143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48,721.64 06/05/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184142135
Principal investigator 1 PFIZER INC. $23,297.04 06/02/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228776989
Recipient Regeneron Pharmaceuticals, Inc. $265.66 05/29/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184115741
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $462.81 05/23/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223273003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $174.00 05/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184142077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,757.37 05/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184142079
Principal investigator 1 BeiGene, Ltd. $87,487.00 05/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190323054
Principal investigator 1 BeiGene, Ltd. $5,908.00 05/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190324470
Principal investigator 1 Genentech, Inc. $57,531.00 04/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Inflamed Solid Tumors PD1 TIM3 Ph1 study in Solid Tumors No dispute reported 06/30/2026 1211564084
Principal investigator 1 BeiGene, Ltd. $4,535.00 04/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1190323002
Principal investigator 1 BeiGene, Ltd. $2,553.00 04/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190324472
Principal investigator 1 PFIZER INC. $97,287.84 04/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228780712
Principal investigator 1 BeiGene, Ltd. $5,648.00 03/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190324468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,566.00 03/19/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184141775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $66,015.55 03/07/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
TAK-280-1501 No dispute reported 06/30/2026 1223272973
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,900.00 03/07/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
TAK-280-1501 No dispute reported 06/30/2026 1223272975
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,850.00 03/07/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
TAK-280-1501 No dispute reported 06/30/2026 1223272977
Principal investigator 1 PFIZER INC. $77,382.50 02/18/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 1 STUDY OF SGNB7H4V IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228794266
Principal investigator 1 BeiGene, Ltd. $12,413.00 01/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190324466